Health Care Down as Traders Brace for Regulatory Changes — Health Care Roundup
Provided by
Dow Jones
Health-care companies fell as traders braced for regulatory changes.
Eli Lilly has caught up with soaring demand for its tirzepatide weight-loss and diabetes medication following two years of shortages, according to the Food and Drug Administration. Shares of Humana lost more ground, and the provider of health insurance for government-backed plans has now lost almost half of its market value for the year to date, partly due to slipping ratings on its Medicare plans.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
October 03, 2024 17:53 ET (21:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
United States